Rajendra Kotadia
Ganciclovir (GCV), an acyclovir analogue,proved to have excellent antiviral activity against human Cytomegalovirus (CMV), a leading cause of congenital infections worldwide. Ganciclovir (GCV), given intravenously (i.v.) at 5 mg/kg of body weight once daily, or orally as capsules at 1,000 mg three times a day (TID), is the standard drug regimen for both the treatment and prevention of CMV disease. . However, i.v. GCV is an inconvenient drug regimen for long-term use, requiring i.v. catheters and might leads to sepsis. Although GCV capsules are more convenient, the low relative bioavailability (6%) limits the concentrations in serum
